Clinical Trials
20 trialsNCT06995677 2026-05-20
SURF302
Tyra Biosciences, Inc
Phase 2 Recruiting
NCT05951179 2026-05-18
ADVANCED-2
Protara Therapeutics
Phase 2 Recruiting
NCT07283835 2026-04-23
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Lepu Biopharma Co., Ltd.
Phase 2 Recruiting
NCT06833073 2026-04-06
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT03945162 2025-11-24
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Theralase® Technologies Inc.
Phase 2 Recruiting
NCT06829823 2025-10-16
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT06663137 2025-06-13
HGNMIBC
Relmada Therapeutics, Inc.
Phase 2 Recruiting
NCT04387461 2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2 Completed
NCT05943379 2023-07-13
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT03719300 2020-08-19
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT04498702 2020-08-13
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase 2 Completed
NCT00595088 2019-04-30
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd.
Phase 2 Completed
NCT01687244 2017-07-24
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
FKD Therapies Oy
Phase 2 Completed
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT00192049 2007-05-17
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00191711 2007-01-26
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
Eli Lilly and Company
Phase 2 Completed